3360:HKEXFar East Horizon Limited Analysis

Ship Healthcare Holdings is trading at ¥2,431, comfortably above its identified support of ¥2,400.5 and well below the resistance of ¥2,799, suggesting limited upside in the immediate term. The 20‑day and 50‑day SMAs sit at ¥2,620 and ¥2,646 respectively, indicating the price is still below both moving averages and the trend remains neutral. A 14‑day RSI of 29.9 places the stock in oversold territory, while the MACD histogram is negative and the signal line is bearish, hinting at potential further downside. Volatility over the past 30 days is elevated at roughly 28 %, and trading volume has been on a decreasing trajectory, raising concerns about short‑term liquidity. However, the forward P/E of 13.2 versus the industry average of 26.2 signals a substantial valuation discount. The dividend yield of 2.47 % with a payout ratio near 36 % adds income appeal.
Fundamentally, revenue grew 3.7 % year‑over‑year and margins remain thin, but the company enjoys a diversified portfolio spanning medical devices, supplies, life‑care facilities and pharmacy services, which should benefit from Japan’s aging demographics. The balance sheet shows ample cash of ¥78.5 bn against debt of ¥27.6 bn, keeping leverage modest despite a high debt‑to‑equity figure derived from market values. With a beta under 0.2, the stock is insulated from broader market swings, and the current upside/downside projection of +23 % / –16 % aligns with the fair‑value target range of ¥2,750‑¥2,995. Taken together, the stock appears undervalued, dividend‑sustainable, and positioned for steady long‑term growth while presenting short‑term risk from technical weakness.